Americans pay two to three times more for prescription drugs than people in peer countries — not because they use more drugs or get better ones, but because of how the pricing system is structured. This hub documents how that system works, who bears the consequences, and what reform approaches are currently being debated. The deeper argument about pharmaceutical R&D costs, public research funding, and how the industry’s justification for high prices holds up under scrutiny is documented in the Pharmaceutical Research and Pricing hub, part of the Healthcare and the Profit System cluster.
The hub is in the early Sentiment stage. The forum space for this issue is open. If you have direct experience with drug costs — rationing medication, navigating prior authorization, choosing between prescriptions and other necessities — that experience is what this hub is designed to surface.
Start Here
What Americans Pay and Why: The Basics of Drug Pricing — How US prices compare to peer countries and how the pricing chain works from manufacturer to patient.
The Insulin Crisis: A Case Study in Pricing Failure — A drug invented in 1921 whose US list price increased 1,200 percent, and what that produced for patients who depend on it.
Understanding the Issue
Who Sets the Price: Manufacturers, PBMs, and the Rebate System — The largely invisible intermediaries that negotiate drug prices and how the rebate system creates incentives for high list prices.
What Other Countries Do Differently: International Drug Pricing Models — Reference pricing, centralized negotiation, health technology assessment, and what the evidence shows about effectiveness and tradeoffs.
The Policy Landscape: What Reform Proposals Are on the Table — Medicare negotiation, price transparency, PBM reform, reference pricing, and importation from Canada.
What Uninsured and Underinsured Patients Actually Pay — List price, cash price, patient assistance programs, and the documented gaps for people without adequate coverage.
Chronic Illness and Ongoing Costs: What Long-Term Drug Dependency Means Financially — Annual out-of-pocket costs for patients with diabetes, MS, HIV, and rheumatoid arthritis — and documented effects of cost-driven non-adherence.
Drug Shortages: When the Problem Isn’t Just Price — Generic manufacturing concentration, group purchasing organizations, and the supply chain dynamics behind recurring shortages.
Rights and Consequences
What Drug Prices Cost People: A Rights-First Look — The documented human cost of the current pricing system — rationing, mortality, and the disparity in who bears the burden.
Institutional Interests
Who Benefits from Current Drug Prices: Institutional Actors in the Prescription Drug Pricing System — Pharmaceutical manufacturers, pharmacy benefit managers, and the documented lobbying and legal strategies that preserve the current structure.
History and Context
The History of U.S. Drug Pricing: How the Current System Developed — From the Pure Food Act through Hatch-Waxman, Part D, and the IRA — the legislative history that shaped current pricing.
Why Medicare Couldn’t Negotiate Drug Prices — Until Recently — The 2003 non-interference clause, how it was shaped, and what the Inflation Reduction Act changed.
How the System Works
The Patent System and Drug Pricing: How Exclusivity Works — How pharmaceutical patents and market exclusivity periods interact to extend effective monopoly pricing, including evergreening strategies.
Generics and Biosimilars: How They Work and Why They Don’t Always Lower Prices — The Hatch-Waxman generic pathway, the biosimilar challenge, and why price competition is slower than expected.
From Lab to Pharmacy: How Drugs Get Approved and What It Costs — The clinical trial pipeline, R&D cost claims, the role of public research funding, and how pricing decisions are made before approval.
Join the Conversation
The forum space for this issue is open. If you have direct experience with drug costs — rationing medication, navigating prior authorization, choosing between prescriptions and other necessities — that experience is what this hub is designed to surface.
Join the forum discussion — or read How to Participate for an overview of how the forum works and what kinds of contributions are most